VCYT (Veracyte, Inc.) Stock | Pipeline, Insider Trades & Financials

Jul 9, 2026

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Veracyte, Inc. has announced that it will release its financial results for the second quarter of 2026 on July 30, 2026. Following the release, company management will host a conference call and webcast to discuss the results and provide a business update. The call is scheduled for 4:30 p.m. Eastern Time.

Jun 3, 2026

Expanding the Afirma GRID proprietary research-use-only database

Veracyte has expanded its Afirma GRID research database to enhance thyroid nodule diagnostics. The tool now includes 50 data points, adding five new thyroid-specific signatures. This expansion aims to support researchers in uncovering insights into thyroid cancer biology and improve personalized treatment for patients. The GRID tool has already facilitated numerous award-winning research presentations.

Jun 1, 2026

VCYTPhases

ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

The ENZAMET trial presented at the ASCO Annual Meeting demonstrates that Veracyte's Decipher Prostate test can effectively identify which men with metastatic prostate cancer will benefit from adding chemotherapy to standard hormonal therapy. This represents the first Level 1B evidence for genomic-guided treatment decisions in this context. The findings also reinforce the test's utility in high-risk localized prostate cancer.

Jun 1, 2026

VCYTPhases

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

The OPTIMA trial has demonstrated that Veracyte's Prosigna test can effectively guide chemotherapy decisions for patients with early-stage, ER-positive HER2-negative breast cancer. The trial found that more than two-thirds of participants could safely avoid chemotherapy based on their Prosigna test results. This represents a significant shift in treatment approaches, allowing for reduced side effects and improved patient outcomes.

May 22, 2026

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

Veracyte, Inc. announced that data from the OPTIMA and ENZAMET trials will be presented at the ASCO 2026 Annual Meeting. The OPTIMA trial focuses on using the Prosigna test to guide chemotherapy decisions in high-risk breast cancer patients. The ENZAMET trial evaluates the Decipher test's ability to predict treatment benefits in metastatic prostate cancer. These findings may significantly influence treatment personalization and decision-making in oncology.

May 22, 2026

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Veracyte has announced an upcoming investor call scheduled for June 1, 2026, where they will discuss findings from the ASCO conference. The call aims to provide insights into the company's latest research and developments. Further details about the findings have not been disclosed in the announcement.

May 20, 2026

▲ +8.4%on this newsshared move

Veracyte to Participate in Upcoming June 2026 Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) has announced its participation in upcoming investor conferences. The company will provide live audio webcasts of its presentations, which will be accessible on their website. This initiative reflects Veracyte's ongoing commitment to engage with investors and showcase its advancements in cancer diagnostics.

May 19, 2026

Veracyte to Participate in Upcoming Investor Conferences

Veracyte is set to participate in upcoming investor conferences, indicating its ongoing engagement with the investment community. The article does not provide specific details about the conferences or the topics to be discussed. This participation may enhance Veracyte's visibility among investors and stakeholders.

May 13, 2026

The future of personalized bladder cancer care

The article discusses advancements in bladder cancer research, particularly focusing on the Decipher Bladder Genomic Classifier, which aids in personalizing treatment based on tumor biology. It highlights the importance of understanding tumor aggressiveness and progression risks. The ongoing collaboration within the urologic oncology community aims to improve patient outcomes through innovative research and clinical studies.

May 5, 2026

Veracyte Announces First Quarter 2026 Financial Results

Veracyte's announcement of its first quarter 2026 financial results is notably lacking in detail. The article does not provide any insights into the company's financial performance or future projections. This absence of information may raise concerns among stakeholders regarding the company's transparency and strategic direction.

Apr 15, 2026

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Veracyte, Inc. will announce its financial results for Q1 2026 on May 5, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, where management will discuss the results and provide a business update. The event will be accessible via the company's website.

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Veracyte, Inc. reported strong financial results for Q4 and full year 2025, with total revenue reaching $140.6 million in Q4, a 19% increase year-over-year. The company highlighted significant growth in its testing revenue and net income, which surged by 705%. Looking ahead, Veracyte anticipates continued growth in 2026, driven by new product launches and an expected revenue increase of 10% to 13%.

Feb 25, 2026

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Veracyte, Inc. will present over 15 abstracts at the 2026 ASCO GU Symposium, focusing on its Decipher Prostate and Bladder tests. These studies emphasize the role of genomic testing in guiding treatment decisions for urologic cancers. Notably, the SURE-102 trial will explore genomic subtyping's impact on bladder cancer treatment. The conference is set for February 26-28 in San Francisco.

Feb 5, 2026

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Veracyte, Inc. will announce its financial results for Q4 and full-year 2025 on February 25, 2026. Following the release, management will hold a conference call and webcast to discuss the results and provide a business update. The call is scheduled for 4:30 p.m. ET and will be accessible via the company's website.

Dec 30, 2025

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be accessible via live audio webcasts on the company's website, with replays available for 30 days. Veracyte aims to transform cancer care through its advanced diagnostics platform.

Oct 8, 2025

VCYTPhases

Fighting breast cancer with genomic testing

The article discusses the significance of genomic testing in breast cancer treatment, particularly focusing on the Prosigna Breast Risk of Recurrence test. With breast cancer being the most common cancer among women, innovative approaches like the OPTIMA trials aim to determine if high-risk patients can safely avoid chemotherapy. The results from these trials are expected to provide crucial insights into personalized treatment strategies.

Sep 19, 2025

Innovation in prostate cancer care

September marks Prostate Cancer Awareness Month, highlighting the ongoing research and innovation in prostate cancer care. The Decipher Prostate test offers genomic insights that help clinicians tailor treatment decisions, improving outcomes for patients. With rising diagnosis rates and mortality, advancements in personalized medicine are crucial for effective management of the disease.

Jun 12, 2025

Real-world utility with Afirma GSC Benign Results

The Afirma GSC test has proven effective in ruling out malignancy in indeterminate thyroid nodules, with a low false negative rate of 1.5%. A study evaluating over 800 nodules showed that Afirma GSC's performance aligns with validation metrics, helping to prevent unnecessary surgeries. Most patients with benign results remained stable during follow-up, reinforcing its utility in clinical management.

May 21, 2025

Bringing clarity to bladder cancer care

The article highlights the challenges faced by bladder cancer patients and the advancements in genomic technology that aid treatment decisions. With nearly 85,000 diagnoses expected in the U.S. this year, the article discusses the importance of the Decipher Bladder test and the development of a minimal residual disease test to enhance patient outcomes. These innovations aim to provide better insights for personalized care amidst the complexities of bladder cancer treatment.

Apr 23, 2025

Afirma GSC: Benign Result

A meta-analysis of Afirma GSC evaluated nearly 2000 indeterminate thyroid nodules across 13 sites, revealing that its real-world performance either matched or exceeded clinical validation metrics. Key improvements were noted in specificity, positive predictive value, and benign call rate. The findings underscore the test's reliability in guiding treatment decisions for patients with indeterminate thyroid nodules.

Feb 5, 2025

Afirma GSC: The tumor microenvironment

The article discusses the tumor microenvironment (TME) and its critical role in cancer progression. It explains various components of the TME, including stromal tissue, cancer-associated fibroblasts, angiogenesis, and immune cells. The Afirma GSC platform utilizes whole-transcriptome analysis to capture the complexity of cancer, aiding in research and potential novel discoveries.

Nov 4, 2024

Afirma GSC: Patient report

The Afirma GSC patient report highlights the significance of molecular profiles like BRAF-like and RAS-like in understanding tumor behavior. These profiles were developed from extensive research on thyroid cancers, revealing correlations between genetic alterations and tumor characteristics. The report emphasizes the complexity of cancer development and the utility of whole-transcriptome analysis in characterizing nodules.

Sep 26, 2024

Afirma GSC: Fresh FNA Sample vs. Slide Scraping

Veracyte emphasizes the importance of using fresh Fine Needle Aspiration (FNA) samples for its Afirma Genomic Sequencing Classifier (GSC). Studies indicate that slide scraping can lead to inadequate genomic material and missed molecular alterations. Consequently, Afirma GSC is exclusively available for dedicated FNA samples to ensure the highest accuracy in testing.

Aug 15, 2024

Afirma GSC: Whole-transcriptome analysis

Veracyte's Afirma Genomic Sequencing Classifier (GSC) utilizes whole-transcriptome analysis to enhance cancer diagnostics, particularly in thyroid nodule management. By examining gene expression through transcripts, it offers insights that DNA analysis alone cannot provide. This method captures the complexity of cancer, leveraging both mitochondrial and chromosomal data for improved classification of lesions.

Aug 13, 2024

▲ +8.8%on this newsshared move

Afirma GSC: Oncocytic cell lesions

Veracyte's Afirma Genomic Sequencing Classifier (GSC) effectively classifies oncocytic cell lesions, which are difficult to diagnose due to their similarities with benign conditions. The GSC utilizes two indices: the Oncocytic Cell Index and the Oncocytic Neoplasm Index, achieving 89% sensitivity. This advancement aims to enhance patient outcomes by improving diagnostic accuracy.

Jul 12, 2024

Afirma GSC: Assessing the data in patient reports

Veracyte's Afirma GSC utilizes a two-step process to assess thyroid nodules, providing either a Benign or Suspicious call. The Suspicious result indicates a 50% risk of malignancy, which can be refined by specific genetic variants. The company regularly updates its reports based on ongoing literature reviews to ensure accuracy and reliability for physicians.

Jul 12, 2024

Afirma GSC: Yes, we can leave more thyroids intact

The Afirma Genomic Sequencing Classifier (GSC) has shown to significantly reduce unnecessary thyroid surgeries in patients with indeterminate nodules. A study revealed a 28% decrease in surgical rates for those tested with the GSC compared to those without testing. Notably, patients with Bethesda IV nodules experienced a 46% reduction in surgeries. The findings emphasize the importance of offering genomic testing to improve patient outcomes.

Jun 19, 2024

VCYTFDA Updates

New Medicare coverage for the Afirma GSC

Veracyte's Afirma Genomic Sequencing Classifier (GSC) has received expanded Medicare coverage for patients with Bethesda V thyroid nodules, enhancing access to personalized treatment options. This decision stems from a new Local Coverage Determination and aims to guide surgical strategies based on genomic characteristics. The Afirma GSC has proven effective in identifying cancer risks, potentially reducing unnecessary surgeries.

Jun 5, 2024

Afirma GSC: Challenges with repeat FNA

The article discusses the challenges associated with repeat fine needle aspiration (FNA) biopsies for thyroid nodules with indeterminate cytology results. It highlights low concordance rates among cytologists and the limited clinical actionability of repeat biopsies. The 2015 ATA guidelines emphasize the importance of molecular analysis through Afirma GSC to enhance patient care and reduce unnecessary procedures.

May 30, 2024

Afirma GSC: TERT DNA Analysis

Veracyte has enhanced its Afirma GSC platform to include TERT DNA analysis, which helps physicians assess thyroid nodules more effectively. This analysis identifies critical molecular alterations associated with cancer, offering insights into the likelihood of malignancy and aggressive disease. The process for ordering this analysis remains straightforward for clinicians.

May 17, 2024

Fair access to molecular testing

The article discusses advancements in molecular testing for prostate cancer, particularly the Decipher Prostate test, which aids in personalized treatment decisions. It highlights the importance of educating both clinicians and patients about these tests to improve access and utilization. Despite progress, only a small percentage of patients currently benefit from molecular testing, particularly among underserved communities.

Mar 5, 2024

Clinical evidence generation and guidelines

Veracyte's Decipher Prostate Genomic Classifier has been recognized in the updated NCCN Guidelines for prostate cancer, achieving level 1B evidence for its use in patient treatment. The company emphasizes its commitment to evidence generation through collaborations and advanced testing methodologies. Additionally, the recent acquisition of C2i Genomics enhances Veracyte's capabilities in developing minimal residual disease tests, further advancing its diagnostic platform.

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform Grew full-year revenue to between $3

Veracyte, a cancer diagnostics company, announced its preliminary financial results for 2023, reporting a revenue increase of 21% to between $358 million and $359 million. The company has also entered a definitive agreement to acquire C2i Genomics, enhancing its diagnostic platform with minimal residual disease capabilities. This acquisition is expected to aid in monitoring cancer treatment efficacy and improve patient outcomes. Veracyte anticipates a revenue growth of 10% to 12% for 2024, although certain revenue lines may decline.

Afirma GSC: Unlocking the whole transcriptome

Veracyte's Afirma GSC employs whole-transcriptome analysis to classify thyroid nodules as benign or suspicious. It utilizes multiple classifiers and machine learning algorithms to enhance accuracy. The test has significantly improved the classification of oncocytic lesions and has helped over 250,000 patients avoid unnecessary surgeries. Future research possibilities using genomic data are also highlighted.

Jul 12, 2021

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth SOUTH SAN FRANCISCO, Calif., July 12, 2021 --- Veracyte, Inc. (Nasdaq VCYT), a global genomic diagnostics company, today announced the appoin

Jun 1, 2021

Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cance

Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference

Feb 4, 2021

Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE)

Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock SAN FRANCISCO, Calif. (BUSINESS WIRE) February 4, 2021 Veracyte, Inc. (Nasdaq: VCYT) (the Company ) today announced the pricing of an underwritten public offering of 7,432,433 shares of it

Feb 3, 2021

Veracyte To Acquire Decipher Biosciences Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expec

Veracyte To Acquire Decipher Biosciences Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth Tina Nova, Ph.D., Decipher Biosciences presid

Aug 4, 2020

Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE)

Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) August 4, 2020 Veracyte, Inc. (Nasdaq: VCYT) (the Company ) today announced the pricing of an underwritten public offering of 6,000,000 shares of its co

Oct 22, 2019

Veracyte Announces Third Quarter 2019 Financial Results and Business Progress Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swa

Veracyte Announces Third Quarter 2019 Financial Results and Business Progress Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swab Test for Lung Cancer Early Detection Conference Call

Jul 30, 2019

Veracyte Announces Second Quarter 2019 Financial Results Revenue Grew 32% to $30.1 Million Genomic Test Volume Grew 26% to 9,663 Company Raises 2019 Full-Year Revenue Guidance Conference Call and Webcast Today at 5:00 p.

Veracyte Announces Second Quarter 2019 Financial Results Revenue Grew 32% to $30.1 Million Genomic Test Volume Grew 26% to 9,663 Company Raises 2019 Full-Year Revenue Guidance Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 30, 2019 -- Ver

May 2, 2019

Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE)

Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) May 2, 2019 Veracyte, Inc. (Nasdaq: VCYT) (the Company ) today announced the pricing of an underwritten public offering of 5,500,000 shares of its commo

Oct 29, 2018

Veracyte Announces Third Quarter 2018 Financial Results Revenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent Company Increases Annual Revenue Guidance and Lowers Cash Burn Guidance for 2018 Conference Cal

Veracyte Announces Third Quarter 2018 Financial Results Revenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent Company Increases Annual Revenue Guidance and Lowers Cash Burn Guidance for 2018 Conference Call and Webcast Today at 4:30 p.m. EDT SOUTH SAN FRANCISC

Jul 25, 2018

Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE)

Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) July 25, 2018 Veracyte, Inc. (Nasdaq: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a

Jul 23, 2018

Veracyte Announces Second Quarter 2018 Financial Results Revenue up 24% to $22.8 Million Compared to Second Quarter 2017 Increasing Revenue and Narrowing Cash Burn Guidance for Full-year 2018 Conference Call and Webcast

Veracyte Announces Second Quarter 2018 Financial Results Revenue up 24% to $22.8 Million Compared to Second Quarter 2017 Increasing Revenue and Narrowing Cash Burn Guidance for Full-year 2018 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July

May 1, 2018

Veracyte Announces First Quarter 2018 Financial Results Grew Revenue by 22%, to $20.0 Million Executed In-Network Contract with Anthem Company Raises 2018 Annual Revenue Guidance Conference Call and Webcast Today at 4:30

Veracyte Announces First Quarter 2018 Financial Results Grew Revenue by 22%, to $20.0 Million Executed In-Network Contract with Anthem Company Raises 2018 Annual Revenue Guidance Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 1, 2018 -- Ve

Feb 27, 2018

Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook Full-Year Revenue Grew 11%, to $72.0 Million Announces Upcoming Launch of Afirma Xpression Atlas Platform Conference

Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook Full-Year Revenue Grew 11%, to $72.0 Million Announces Upcoming Launch of Afirma Xpression Atlas Platform Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANC

Jan 8, 2018

Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth Company Reiterates 2017 Revenue and Cash Burn Guidance

Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth Company Reiterates 2017 Revenue and Cash Burn Guidance SOUTH SAN FRANCISCO, Calif., January 8, 2018 --- Veracyte, Inc. (NASDAQ: VCYT) today announced key business initiatives, including s

Nov 6, 2017

Veracyte Announces Third Quarter 2017 Financial Results Reports Revenue of $17.5 Million for the Third Quarter 2017 Highlights Business Progress Conference Call and Webcast Today at 4:30 p.m.

Veracyte Announces Third Quarter 2017 Financial Results Reports Revenue of $17.5 Million for the Third Quarter 2017 Highlights Business Progress Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 6, 2017 --- Veracyte, Inc. (NASDAQ: VCYT) t

Jul 31, 2017

Veracyte Announces Second Quarter 2017 Financial Results Reports 25% Revenue Growth, to $18.4 Million, and 37% Improvement in Loss from Operations Over Prior Year Conference Call and Webcast Today at 4:30 p.m.

Veracyte Announces Second Quarter 2017 Financial Results Reports 25% Revenue Growth, to $18.4 Million, and 37% Improvement in Loss from Operations Over Prior Year Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2017 -- Veracyte, Inc. (N

Dec 13, 2016

Veracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors

Veracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors SOUTH SAN FRANCISCO, Calif., December 13, 2016 --- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving dia

Nov 22, 2016

Veracyte Announces that CMS Will Maintain Historic Medicare Reimbursement Rate for the Afirma Gene Expression Classifier in 2017

Veracyte Announces that CMS Will Maintain Historic Medicare Reimbursement Rate for the Afirma Gene Expression Classifier in 2017 SOUTH SAN FRANCISCO, Calif., November 22, 2016 --- Veracyte, Inc. (NASDAQ: VCYT) announced today that the Centers for Medicare and Medicaid Services

Nov 21, 2016

Veracyte Appoints Keith Kennedy as Chief Financial Officer

Veracyte Appoints Keith Kennedy as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., November 21, 2016 --- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced

Nov 2, 2016

Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock

Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif., November 2, 2016 Veracyte, Inc. (NASDAQ: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offeri

Nov 1, 2016

Veracyte Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., November 1 , 2016 Veracyte, Inc. (NASDAQ: VCYT) today announced that it has commenced an underwritten public offering of its common

Veracyte Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., November 1, 2016 Veracyte, Inc. (NASDAQ: VCYT) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by Veracyte. In

Sep 30, 2016

Veracyte Releases Statement on CMS's Final 2017 Gapfill Rate for the Afirma Gene Expression Classifier

Veracyte Releases Statement on CMS's Final 2017 Gapfill Rate for the Afirma Gene Expression Classifier SOUTH SAN FRANCISCO, Calif., September 30, 2016 -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing diagnostic uncertainty, today issued the st

Aug 3, 2016

Veracyte Announces Second Quarter 2016 Financial Results

Veracyte Announces Second Quarter 2016 Financial Results Revenue and Afirma GEC Volume Each Increased 23%, Compared to the Second Quarter of 2015 Increased In-Network, Contracted Lives to Over 140 Million, Adding Two Key Payers Conference Call and Webcast Today at 4:30 p.m. Ea

May 5, 2016

Veracyte Announces First Quarter 2016 Financial Results Revenue Increased 21% and Afirma GEC Volume Grew 33%, Compared to Same Quarter in 2015 Conference Call and Webcast Today at 4:30 p.m.

Veracyte Announces First Quarter 2016 Financial Results Revenue Increased 21% and Afirma GEC Volume Grew 33%, Compared to Same Quarter in 2015 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 5, 2016 Veracyte, Inc. (NASDAQ: VCYT) today announc

Mar 10, 2016

Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook 30% Growth in Revenue, 38% Increase in Afirma GEC Volume for 2015 Increased Covered Lives for

Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook 30% Growth in Revenue, 38% Increase in Afirma GEC Volume for 2015 Increased Covered Lives for Afirma to 180 Million, In-Network Contracted Lives to 130 Million Concluding U

Nov 16, 2015

Veracyte Names Tina S. Nova, Ph.D. to Its Board of Directors

Veracyte Names Tina S. Nova, Ph.D. to Its Board of Directors SOUTH SAN FRANCISCO, Calif. November 16, 2015 Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Tina S. Nova, Ph.D. has been appointed to it

Nov 5, 2015

Veracyte Announces Third Quarter 2015 Financial Results Revenue Grew 25% and Afirma GEC Test Volume Increased 46%, Compared to Third Quarter 2014 Conference Call and Webcast Today at 5:15 p.m.

Veracyte Announces Third Quarter 2015 Financial Results Revenue Grew 25% and Afirma GEC Test Volume Increased 46%, Compared to Third Quarter 2014 Conference Call and Webcast Today at 5:15 p.m. ET SOUTH SAN FRANCISCO, Calif., November 5, 2015 - Veracyte, Inc. (NASDAQ: VCYT) tod

Sep 27, 2015

Veracyte Statement on CMS s Preliminary 2016 Clinical Laboratory Fee Schedule and Proposed PAMA Rule South San Francisco, Calif.

Veracyte Statement on CMS s Preliminary 2016 Clinical Laboratory Fee Schedule and Proposed PAMA Rule South San Francisco, Calif. September 27, 2015 Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today issued the follow

Aug 13, 2015

Veracyte Announces Second Quarter 2015 Financial Results Revenue Increased 37% Compared to Second Quarter 2014 Conference Call and Webcast Today at 4:30 p.m.

Veracyte Announces Second Quarter 2015 Financial Results Revenue Increased 37% Compared to Second Quarter 2014 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 13, 2015 Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the

May 14, 2015

Veracyte Announces First Quarter 2015 Financial Results First Quarter Revenue Increased 50%, Compared to the Same Quarter in 2014 Conference Call and Webcast Today at 5:00 p.m.

Veracyte Announces First Quarter 2015 Financial Results First Quarter Revenue Increased 50%, Compared to the Same Quarter in 2014 Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 14, 2015 Veracyte, Inc. (NASDAQ: VCYT) today reported financial

Apr 23, 2015

Veracyte, Inc. Announces $40 Million Private Placement South San Francisco, Calif.

Veracyte, Inc. Announces $40 Million Private Placement South San Francisco, Calif., April 23, 2015 Veracyte, Inc. (NASDAQ: VCYT) today announced that it has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement. Under th

Mar 19, 2015